NEW YORK — Jazz Pharma, Roche’s combination therapy for lung cancer gets US approval, the companies announced on Friday. The therapy targets advanced non-small cell lung cancer (NSCLC).
The approval allows physicians to prescribe the therapy to patients with specific genetic markers. Clinical trials showed improved survival rates and better overall outcomes compared to standard treatments.
Jazz Pharma, Roche’s combination therapy for lung cancer gets US approval after rigorous review by the Food and Drug Administration. Regulators highlighted its effectiveness in reducing tumor growth and improving patient quality of life.
The combination therapy pairs Jazz Pharma’s targeted drug with Roche’s immunotherapy agent. Together, the two drugs work to slow cancer progression and boost the immune system’s response to tumors.
Experts say the approval is a significant milestone in lung cancer treatment. NSCLC accounts for approximately 85% of all lung cancer cases, making new treatment options critical for patient survival.
Jazz Pharma, Roche’s combination therapy for lung cancer gets US approval, offering hope to thousands of patients nationwide. Health professionals expect the therapy to become a key part of treatment protocols for eligible patients.
Patient advocacy groups welcomed the approval, noting that access to innovative therapies can improve outcomes and provide new options for those who have exhausted standard treatments.
The therapy will be available in major cancer centers across the United States. Both companies said they are working with insurers to ensure broad patient access.
Analysts predict that the approval could strengthen Jazz Pharma and Roche’s market position in oncology, as demand for advanced lung cancer treatments continues to grow globally.
Overall, the FDA’s decision marks a critical step forward in personalized cancer therapy. Patients with advanced NSCLC now have an additional evidence-based option to help manage their disease and potentially extend survival.
Read More : Jazz was declared as Most Inclusive Company in Annual Global DEI Benchmarks Awards 2025
